U.S. FDA Approves Finerenone for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

Bayer announced that the US FDA has approved finerenone, the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist, under the brand name Kerendia^®.